Publication

Abstract : The Zika Virus (ZIKV) happens to be one of the recent infections investigated after the Ebola pandemic. It is an arthropod-borne virus (arbovirus) within the family Flaviviridae class. ZIKV is an RNA virus with a single strand, enveloped, icosahedral, non-sectioned, positive sense. It is 40 nm wide and has an outer (E) envelope and a dense inner core. The ZIKV can be transmitted by two methods: human and human-to-human vectors. The vector transmission is by Aedes spp. Mosquitoes and diseases outside Africa are transmitted by Aedes aegypti. Originating in Nigeria in 1947 it was reported as a mild illness and from a rhesus monkey. With a certain passage of time earned significant attention from healthcare organisations for the human population. Many clinical symptoms in adults in French Polynesia have been recorded, ranging from mild illness to severe neurological problems such as Guillain-Barré syndrome. Other symptoms include encephalitis microencephaly, meningoencephalitis, myelitis, paraesthesia, vertigo, facial and ophthalmological paralysis (photophobia and hypertensive iridocyclitis) and auditory manifestations. In this review, the clinical aspects and other therapeutic responses are studied here to understand the approach more treating symptoms arising with the infection of the Zika virus. Various complications have been studied in this review and diagnosis have been performed to identify the presence in the human body and also take clinical measures on alleviating the symptoms of the infected patients.